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ABSTRACT
Background: Pancuronium, vecuronium, rocuronium, and mivacurium are
ondepolarizing neuromuscular blocking agents that affect the cardiovascular system
ith different potencies. Their cardiovascular effects are clinically significant in the
nesthetic management of patients, particularly those undergoing cardiac surgery.
Objective:We aimed to compare the cardiac effects of these compounds, such
as heart rate and developed force, in one species under identical experimental
conditions in isolated rat atria.
Methods: The left or right atria of rats were removed and suspended in organ
baths. Pancuronium, vecuronium, rocuronium, or mivacurium were added cumula-
tively (10–9–10–5 M) in the presence and absence of the nonselective -blocker
ropranolol (10–8 M) and the noradrenaline reuptake inhibitor desipramine (10–7 M),
nd heart rate changes were recorded in spontaneously beating right atria. Left atrial
reparations were stimulated by electrical field stimulation using a bipolar platinum
lectrode, and the effects of cumulative concentrations of these nondepolarizing
euromuscular blocking agents on the developed force in the presence and absence of
ropranolol (10–8 M) and desipramine (10–7 M) were recorded.
Results: Pancuronium increased heart rate in a dose-dependent manner com-
ared with the control group (P  0.027). Vecuronium, rocuronium, and mivacu-
rium also increased heart rate in a dose-dependent manner, but the changes were not
statistically significant. Although propranolol decreased the pancuronium heart rate
effect (P  0.05), it did not change the heart rate effects with vecuronium, rocuro-
nium, or mivacurium. Desipramine did not change the heart rate effects of vecuro-
nium, rocuronium, mivacurium, or pancuronium. All 4 drugs increased developed
force in a dose-dependent manner; the increases were significant at 10–5 M concen-
ration for pancuronium and at 10–6 and 10–5 M concentrations for vecuronium,
ocuronium, and mivacurium (P  0.038). These increases in developed force were
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Current Therapeutic Researchabolished with the addition of propranolol. Desipramine did not change the devel-
oped force effects of any of the 4 drugs.
Conclusions: The heart rate effect of pancuronium and developed force effects
f pancuronium, vecuronium, rocuronium, and mivacurium may occur via direct
timulation of  receptors. Although our investigation was an in vitro study, the
ffects found may be important especially under pathologic conditions, such as
ypertension, in which patients usually use -blocking agents, which cause 
receptor upregulation. (Curr Ther Res Clin Exp. 2011;72:195–203)
2011 Elsevier HS Journals, Inc.
Key words: atrium, mivacurium, neuromuscular blockers, pancuronium, rat,
rocuronium, vecuronium.
INTRODUCTION
Pancuronium, vecuronium, rocuronium, and mivacurium are nondepolarizing neu-
romuscular blocking agents that affect the cardiovascular system with different
potencies.1 Their cardiovascular effects are clinically significant in the anesthetic
management of patients, particularly those undergoing cardiac surgery. Although
neuromuscular blocking drugs are designed to specifically block nicotinic cholinergic
receptors at the neuromuscular junction, many bind to muscarinic cholinergic recep-
tors on ganglia, nerve endings, and smooth muscle and alter parasympathetically
mediated heart rate.2
The cardiovascular effects of these neuromuscular blocking agents have been
nvestigated in different studies. Both positive inotropic and chronotropic effects have
een reported after pancuronium administration3,4 by increased heart rate and arterial
lood pressure.5,6 In patients with coronary artery disease, pancuronium caused
achycardia, which may result in myocardial ischemia.7 These effects of pancuronium
on heart rate were reported to be due to the increased release and decreased reuptake
of catecholamines at the adrenergic nerve terminal.8 Vecuronium has been reported
to possess sympathomimetic properties that are less pronounced than those produced
by pancuronium,9 and, in contrast to pancuronium, it has been reported to induce
radycardia.10–12 Vecuronium has been used more often than pancuronium because
it has a relatively short duration of action, minimal cardiovascular effects, and an
apparent lack of histamine-releasing properties.13–14
The absence of cardiovascular effects has led investigators to propose using a large
ose of vecuronium to achieve a shorter onset of action,15–17 and it has been offered
as a better alternative to pancuronium for long-lasting neuromuscular blockade in
patients with coronary artery disease during opioid anesthesia.18
Clinical use of rocuronium has shown that it does not produce significant cardiac
ffects,6 except minor hemodynamic changes.19 Mivacurium has been reported to
ause transient tachycardia and hypotension,20,21 and has been offered in patients who
equire hemodynamic stability throughout the surgical procedure.22
In the present study we aimed to compare the cardiac effects of neuromuscular
Open access under the Elsevier OA license.lockers pancuronium, vecuronium, rocuronium, and mivacurium under identical
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force and the possible underlying mechanisms at rat atrial tissue after exposure to
cumulative doses of these drugs.
METHODS
Animals
All experimental procedures were performed in accordance with the recommen-
ations of the Guide for the Care and Use of Laboratory Animals and approved by the
nimal Care Committee of Cumhuriyet University Medical Faculty. Twenty male
lbino Wistar rats (weighing 180–220 g) were allocated into 3 groups: control (n 
), right atrium for heart rate measurement (n  7), and left atrium for developed
orce measurement (n  7). The rats were injected with pentobarbital sodium (100
mg/kg) and sodium heparin (5000 IU/kg) intraperitoneally, and each heart was
rapidly and carefully excised and placed into Ringer solution at room temperature.
The left or right atrium was then removed and suspended in a water-jacketed organ
bath containing 10 mL of Ringer solution at 37°C with an applied preload of 600 mg.
The Ringer solution contained (mmol/L): 144 Na (sodium ion), 5.3 K (potassium
ion), 1.98 Ca2 (calcium ion), 1.18 Mg2 (magnesium ion), 123.93 Cl– (chloride
on), 2.35 H2PO4
– (dihydrogen phosphate ion), 25 HCO3
– (bicarbonate ion), 1.18
SO4
2– (sulfate ion), and 10 glucose. The pH of the solution was 7.4, and the solution
was gassed with a mixture of 95% oxygen and 5% carbon dioxide.
Isometric Measurements
The investigators measuring the effects of these agents were blind to the treatment
roups. After mounting in the organ bath, each preparation was allowed to stabilize
or 60 minutes. During this period, the solution in the bath was changed every 15
inutes. The control group received no treatment. The spontaneously beating right
tria received cumulative concentrations (10–9–10–5 mol/L) of pancuronium, vecu-
onium, rocuronium, or mivacurium in the presence and absence of nonselective
-blocker propranolol (10–8 M) and noradrenaline reuptake inhibitor desipramine
(10–7 M). These antagonists had no effect on heart rate or developed force in these
concentrations during preliminary experiments (data not shown). The right atrium
preparations were exposed to each concentration for 20 minutes, and the heart rate
changes were recorded. After the exposure of the highest concentration, the prepa-
ration was washed by Ringer solution and rested for 20 minutes before the next drug
exposure. Left atrial preparations were stimulated by electrical field stimulation using
a bipolar platinum electrode with 2-millisecond constant current square pulses. The
intensity of these stimuli was set at 75 mA, and the applied frequency was 1 Hz (60
beats per minute).1 Every preparation was exposed to electrical impulses for 30
inutes, 5 minutes of exposure for each concentration of drugs. Biological response
f heart tissue (heart rate and developed force) was converted to electrical stimulus
nd recorded on a Grass model 79E polygraph (Grass Technologies, Astro-Med, Inc.,
est Warwick, Rhode Island).
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Drugs used were propranolol and desipramine (Sigma Chemical, St. Louis, Mis-
ouri); vecuronium and rocuronium (NV Organon, Oss, Netherlands); mivacurium
GlaxoSmithKline, Parma, Italy); and pancuronium (Organon Teknika, Istanbul,
urkey). All drugs were dissolved in deionized water freshly on the day of the
xperiment. Stock solutions were stored at 20°C.
Statistical Analysis
All data are expressed as mean (SEM). Groups were compared statistically using
eneral linear models of ANOVA followed by Newman-Keuls test and t test, when
ppropriate. Differences were considered to be significant at P  0.05. All analyses
ere performed with Statistica for Windows 6.0 (Statsoft, Inc, Tulsa, Oklahoma).
RESULTS
Pancuronium increased heart rate in a dose-dependent manner compared with the
control group, especially at 10–7, 10–6, and 10–5 M concentrations (P  0.05). This
increase was even more obvious at 10–6 and 10–5 M concentrations. Vecuronium,
ocuronium, and mivacurium also increased heart rate in a dose-dependent manner,
ut the changes were not statistically significant. Although propranolol (10–8 M), a
nonselective -blocker, decreased the pancuronium heart rate effect (P 0.05), it did
not change that of vecuronium, rocuronium, or mivacurium. Desipramine (10–7 M),
a noradrenaline reuptake inhibitor, did not change the heart rate effect of vecuronium,
rocuronium, mivacurium, or pancuronium (Figure 1).
Separately, all 4 drugs increased developed force in a dose-dependent manner; the
increases were significant at 10–5 M concentration for pancuronium and 10–6 and
10–5 M concentrations for vecuronium, rocuronium, and mivacurium (P 0.05). The
ncreases in developed force were abolished by the addition of propranolol. Desipra-
ine (10–7 M) did not change the developed force effects of pancuronium, vecuro-
ium, rocuronium, or mivacurium (Figure 2).
The maximum effects of these drugs on heart rate and developed force are
ummarized in the Table.
DISCUSSION
The cardiovascular effects of nondepolarizing muscle relaxants have been studied in
different animals and also in humans. The isolated heart muscle preparation is useful
in evaluation of the effects of drugs upon myocardial contractility, because such a
preparation allows preload and afterload to be controlled and because it is free of the
influence of neurohumoral responses.3 Pancuronium produced tachycardia and in-
creased arterial pressure; this cardiac stimulation has been attributed to vagolytic
action, a release of norepinephrine from the sympathetic nerve terminals, or inhibi-
tion of neuronal uptake of norepinephrine.9 In another study, the effect of pancuro-
ium on heart rate was connected to, in part, increased release and decreased reuptake
f catecholamines at the adrenergic nerve terminal.8 Plasma adrenaline and noradren-
line concentrations increased when pancuronium was administered to facilitate
racheal intubation23 or after administration of pancuronium to ill neonates.24
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ascular system in experimental animals and in clinical practice.4,25 However, vecu-
ronium has been suggested to have positive chronotropic and inotropic effects, but it
is much less potent than pancuronium in some experimental animals.9 It has been
uggested that the bradycardia effect of vecuronium was due to its direct action or the
ncrease in vagal tone induced by either surgical procedures or other drugs.9 In
patients undergoing coronary artery bypass grafting, rocuronium administration was
associated with significant increases in cardiac index and stroke volume index, but not
with a change in heart rate.26 In a study performed in elderly patients, the authors
reported that rocuronium did not cause tachycardia or hypertension.27 However,
ooth et al28 demonstrated a marked tachycardia after administration of rocuronium.
Appadu and Lambert29 showed an interaction with cardiac muscarinic receptors with
a potency rank order of pancuronium, vecuronium, and rocuronium, respectively.
Savarese et al20 showed a transient decrease in blood pressure after mivacurium
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Figure 1. The effects of (A) pancuronium (10–9–10–5 M), (B) vecuronium (10–9–10–5 M),
(C) rocuronium (10–9–10–5 M), and (D) mivacurium (10–9–10–5 M) on heart rate
at rat atrial tissue. Data are expressed as mean (SEM) (n  5 for each drug).
*P < 0.05 denotes significant difference from the pancuronium control group.administration, but Okanlami et al30 reported that mivacurium inhibited bradycardia
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nerve stimulation. They suggested that mivacurium blocks both M2 and M3 receptors
and that it is a muscarinic antagonist with similar potencies for both M2 and M3
receptors.
The plasma concentration of pancuronium administered to humans during the
first 3 hours is reportedly 500 to 100 ng/mL (90% free form), which is
equivalent to 7  10–7 and 1.4  10–7 M, respectively.31,32 In the present study
we used all neuromuscular blocking drugs at concentrations harmonious with the
study of Cannon et al.17
In the present study, pancuronium increased heart rate in a dose-dependent
anner compared with the control group, especially at high concentrations, but
ecuronium, rocuronium, and mivacurium did not cause a significant increase.
lthough propranolol decreased the heart rate effect of pancuronium, desipramine did
* *
* *
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* * * *
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Figure 2. The effects of (A) pancuronium (10–9–10–5 M), (B) vecuronium (10–9–10–5 M),
(C) rocuronium (10–9–10–5 M), and (D) mivacurium (10–9–10–5 M) on developed
force at rat atrial tissue. Data are expressed as mean (SEM) (n  5 for each
drug). *P < 0.05 denotes significant difference from each control group.ot. All 4 drugs increased developed force in a dose-dependent manner. The increases
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not change the developed force effect of any of the 4 drugs.
The decreased heart rate effect of pancuronium and developed force effects of all 4
agents in the presence of propranolol points to the effects occurring via  receptor
stimulation. If we had not used desipramine, we might hypothesize that the effects
may occur by direct stimulation of  receptors, increased release of endogen nor-
drenaline from sympathetic nerve terminals, and/or decreased reuptake of noradren-
line at nerve terminals. Desipramine did not change their effects, so the effects may
e due to direct stimulation of  receptors.
CONCLUSIONS
Cardiovascular effects of nondepolarizing muscle relaxants are clinically significant in
the anesthetic management of patients in whom long-duration neuromuscular block-
ade is usually required. Pancuronium increased heart rate, and pancuronium, vecu-
ronium, rocuronium, and mivacurium had positive inotropic effects. A positive
inotropic effect of pancuronium was seen at a higher concentration. These effects may
be due to direct stimulation of  receptors. The effects may be important, especially
nder pathologic conditions such as hypertension, in which patients usually use
-blocking agents causing  receptor upregulation. A limitation of the present study
is that it was an in vitro investigation. Further in vivo experimental studies and
Table. Maximum effects of all 4 drugs on heart rate and developed force. Data are given
as mean (SEM).
Group Heart Rate Developed Force
Control 103.6 (2.9) 78.2 (7.2)
Pancuronium 111.7 (3.0)* 90.4 (6.0)*
ancuronium  Propranolol 106.4 (2.5) 83.2 (6.4)
ancuronium  Desipramine 112.2 (2.6)* 91.0 (51)*
ontrol 103.6 (2.7) 76.6 (6.8)
ecuronium 105.6 (2.7) 93.7 (5.3)*
ecuronium  Propranolol 103.8 (2.8) 84.0 (6.2)
ecuronium  Desipramine 107.2 (2.8) 95.0 (5.0)*
ontrol 103.7 (2.3) 72.4 (6.1)
ocuronium 106.9 (2.4) 92.5 (5.1)*
ocuronium  Propranolol 103.7 (2.3) 80.8 (7.4)
ocuronium  Desipramine 108.2 (2.4) 94.0 (5.0)*
ontrol 104.1 (2.6) 70.2 (8.1)*
ivacurium 108.2 (2.6) 91.2 (5.4)
ivacurium  Propranolol 104.4 (2.5) 75.5 (7.2)
ivacurium  Desipramine 112.6 (2.4) 92.6 (4.9)*
P  0.05 denotes significant difference from control of each group.controlled clinical trials are needed to determine whether these findings are correct.
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